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Should ICDs Be Implanted in
All Patients With Dilated
Cardiomyopathy and
Unexplained Syncope?*
Mark E. Josephson, MD
Brookline, Massachusetts
Syncope is a frequent symptom, but when it occurs in the
presence of organic heart disease and there is no obvious
explanation, it carries with it a high incidence of subsequent
sudden death. Several investigators have demonstrated that
unexplained syncope in patients with dilated cardiomyopa-
thy, particularly with clinical congestive heart failure
(CHF), is a predictor of overall mortality and sudden death
(1–3). The risk of sudden death maybe as high as 45%
regardless of the cause of syncope. Although electrophysi-
ologic testing has been useful to risk stratify patients with
“ischemic” cardiomyopathy (20), it has been less useful in
patients with asymptomatic dilated idiopathic cardiomyop-
athy (3–6,11). Only two prior studies have evaluated the
outcome of patients with dilated cardiomyopathies and
syncope treated with implantable defibrillators (ICDs). In
the study of Fazio et al. (21), syncope had already been
documented to be ventricular tachycardia, and most patients
had inducible ventricular arrhythmias at the electrophysi-
ologic study (EPS). In the study of Grimm et al. (22) only
six ICD patients had dilated cardiomyopathies, and these
patients had spontaneous nonsustained ventricular tachycar-
dia.
In this issue of the Journal of the American College of
Cardiology, Knight (23) presents a prospective study compar-
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ing patients with unexplained syncope and idiopathic di-
lated cardiomyopathy treated with devices versus a compa-
rable group of 19 patients with prior cardiac arrests in whom
devices had been implanted. The patients were comparably
matched, although the arrest group had a slightly increased
use of beta-adrenergic blocking agents and amiodarone
therapy than the syncope group, neither of which were
statistically significant. The basic message of this article is
that patients with syncope had a comparable number of
appropriate shocks than those patients who presented with
cardiac arrest, and in those patients who had appropriate
shocks, the time for the first shock was shorter (10 6 14) in
the syncope group than in the arrest group (48 6 47
months; p 5 0.06). This borderline significance may be due
to either the low number of patients included in this study
or the slightly increased use of amiodarone and beta-
blockers in the arrest group. Of note is that the rate of the
arrhythmia for which the first shock was delivered was
comparable. It is significant that no patients in the syncope
group with an ejection fraction greater than 35% received an
inappropriate shock; however, only 3 of the 14 patients had
ejection fractions of greater than 35%. All patients who had
class III functional New York Heart Association status
experienced appropriate shocks, but one patient with class I
symptoms also received an appropriate shock. Thus, al-
though it appears that people with more severe clinical
CHF are likely to receive appropriate shocks, the small
number of patients in this study (with the overlap noted)
limit the usefulness of clinical characteristics as predictors of
those patients who are likely to receive appropriate shocks.
These data might suggest that implantation of ICDs is
appropriate for those patients who have syncope of indeter-
minate cause and in patients with idiopathic dilated cardio-
myopathy. This seems rational because most of the patients
with syncopal episodes had documented ventricular arrhyth-
mias that the device appropriately and successfully treated.
Moreover, on the basis of the results of the AVID trial (24),
devices appear to have a greater benefit and overall survival
than drugs in patients with arrhythmias. However, several
words of caution are applicable before widespread adoption
of this philosophy. First is that this study was small,
including only 14 patients with unexplained syncope. Sec-
ond and most important is that this study was not con-
ducted to see whether the device improved overall mortality.
Although it is true that the ICD delivered appropriate
shocks and probably saved the lives of those people in whom
it delivered appropriate shocks, there was still a 28%
mortality in an average two year follow-up. To recommend
ICDs as initial therapy for unexplained syncope in dilated
cardiomyopathy, one would need to demonstrate that it was
more cost effective than antiarrhythmic drugs with or
without pacemakers in this group of people. Furthermore, it
should be noted that ICDs are not necessarily associated
with improved quality of life. Fifty percent of the patients in
the syncope group received inappropriate shocks, many of
which were due to atrial fibrillation. In view of the fact that
amiodarone is now being widely used in patients with
idiopathic dilated cardiomyopathy as a means to improve
survival, particularly those with atrial fibrillation, a prospec-
tive study will be necessary to assess whether or not ICD
implantation is a preferred method of treatment. In this
cost-conscious environment, this will be mandatory.
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Other issues should be addressed. First is the definition of
unexplained syncope. What may be unexplained in some
physicians’ minds may be obvious in other physicians’
minds. This depends on how careful a history is taken.
Potential abuses of ICDs will occur if reversible or treatable
causes are not sought. For example, drugs are a very frequent
cause of syncope. Use of angiotensin-converting enzyme
inhibitors and diuretics are frequently used in patients with
cardiomyopathy, and they may be important causes of
syncope. Neurocardiac syncope can also occur in patients
with cardiomyopathies, particularly if they are dehydrated.
The classic symptoms of nausea, flushing and weakness are
often not present. Bradycardic events must also be considered
in those patients who have conduction disturbances. Although
conduction disturbances predispose to malignant ventricular
arrhythmias, they also may result in high-degree atrioventric-
ular (AV) block particularly when antiarrhythmic drugs are
used. The same is true for sinus node dysfunction. Amiodarone
is certainly a drug that can produce both AV block and sinus
node dysfunction. Although I am sure the authors excluded all
of these causes, the detail with which such causes are sought
may not be comparable in other settings and in studies
conducted by other physicians.
Secondly, newer ICDs with dual chamber pacing (some
with defibrillation capabilities) are being evaluated, even
dual chamber defibrillation. These devices can provide
important physiologic antibradycardia pacing and decreas-
ing incidents of inappropriate shocks. In addition, there is a
great interest in the use of pacing to synchronize ventricular
activation to improve heart failure. Several companies are
evaluating left ventricular pacing in patients with interven-
tricular conduction defects as a means to improve left
ventricular function. If these devices can be coupled with the
dual chamber defibrillator concept, one would have a device
that can improve ventricular function, convert ventricular
fibrillation or atrial fibrillation when present, provide phys-
iologic rate responsive pacing and allow for the safe use of
antiarrhythmic agents. I am sure trials will soon be under-
way evaluating the advances in technologies in patients with
heart failure, particularly those with dilated cardiomyopa-
thy. Although much enthusiasm abounds in developing
these technologies, this should all be taken in context of the
recognition that once the heart reaches a certain level of
dysfunction, the only alternative to improve survival is
cardiac transplantation.
Reprint requests and correspondence: Dr. M.E. Josephson,
Beth Israel Deaconess Medical Center, 330 Brookline Avenue,
Boston, Massachusetts 02215.
REFERENCES
1. Fruhwald FM, Eber B, Schumacher M, et al. Syncope in dilated
cardiomyopathy is a predictor of sudden cardiac death. Cardiology
1996;87:177–80.
2. Komajda M, Jais JP, Reeves F, et al. Factors predicting mortality in
idiopathic dilated cardiomyopathy. Eur Heart J 1990;11:824–31.
3. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope
in advanced heart failure: high risk of sudden death regardless of origin
of syncope. J Am Coll Cardiol 1993;21:110–6.
4. Das SK, Morady F, DiCarlo L, et al. Prognostic usefulness of
programmed ventricular stimulation in idiopathic dilated cardiomyop-
athy without symptomatic ventricular arrhythmias. Am J Cardiol
1986;58:998–1000.
5. Poll DS, Marchlinski FE, Buxton AE, Josephson ME. Usefulness of
programmed stimulation in idiopathic dilated cardiomyopathy. Am J
Cardiol 1986;58:992–7.
6. Grimm W, Hoffmann J, Menz V, et al. Programmed ventricular
stimulation for arrhythmia risk prediction in patients with idiopathic
dilated cardiomyopathy and nonsustained ventricular tachycardia.
J Am Coll Cardiol 1998;32:739–45.
7. Tramburro P, Wilber D. Sudden death in idiopathic dilated cardio-
myopathy. Am Heart J 1992;124:1035–45.
8. Militianu A, Salacta A, Seibert K, et al. Implantable cardioverter
defibrillator utilization among device recipients presenting exclusively
with syncope or near syncope. J Cardiovasc Electrophysiol 1997;8:
1087–97.
9. Calkins H, Shyr Y, Frumin H, et al. The value of the clinical history
in the differentiation of syncope due to ventricular tachycardia,
atrioventricular block, and neurogenic syncope. Am J Med 1995;98:
365–73.
10. Hummel JD, Strickberger SA, Daoud E, et al. Results and efficacy of
programmed ventricular stimulation with four extrastimuli compared
with one, two, and three extrastimuli. Circulation 1994;90:2827–32.
11. Kushner JA, Kou WH, Kadish AH, Morady F. Natural history of
patients with unexplained syncope and a nondiagnostic electrophysi-
ologic study. J Am Coll Cardiol 1989;14:391–6.
12. Goyal R, Tokano T, Horwood L, et al. Bradycardia-dependent
oversensing by implantable defibrillators (abstr). Pacing Clin Electro-
physiol 1998;91:270.
13. Hook BG, Callans DJ, Hsia HH, et al. Stored ventricular electrogram
analysis in the management of patients with implantable cardioverter
defibrillators. In: Estes NAM, Monolis AS, Wang PJ, eds. Implant-
able Cardioverter Defibrillators: A Comprehensive Textbook. Boston:
Marcel Dekker, 1994:99–101.
14. Luu M, Stevenson LW, Brunken RC, et al. Diverse mechanisms of
unexpected cardiac arrest in advanced heart failure. Circulation 1989;
80:1675–80.
15. Saxon LA, Stevenson WG, Middlekauff HR, Stevenson LW. In-
creased risk of progressive hemodynamic deterioration in advanced
heart failure patients requiring permanent pacemakers. Am Heart J
1993;125:1306–10.
16. Sra JS, Anderson AJ, Sheikh SH, et al. Unexplained syncope evaluated
by electrophysiologic studies and head-up tilt testing. Ann Intern Med
1991;114:1013–9.
17. Krol RB, Morady FM, Flaker GC, et al. Electrophysiological testing
in patients with unexplained syncope: clinical and noninvasive predic-
tors of outcome. J Am Coll Cardiol 1987;10:358–63.
18. Klein AD, Klein GJ, Norris C, Yee R. The etiology of syncope in
patients with negative tilt table and electrophysiology testing. Circu-
lation 1995;92:1819–24.
19. Link MS, Costeas YF, Griffith JL, et al. High incidence of appropriate
implantable cardioverter-defibrillator therapy in patients with syncope
of unknown etiology and inducible ventricular arrhythmias. J Am Coll
Cardiol 1997;29:370–5.
20. Wilbur DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiological
testing and nonsustained ventricular tachycardia. Use and limitations
in patients with coronary artery disease and impaired ventricular
function. Circulation 1990;82:350–8.
21. Fazio G, Veltri EP, Tomaselli G, et al. Long-term follow-up of
patients with nonischemic dilated cardiomyopathy and ventricular
tachycardias treated with implantable cardioverter defibrillators. Pac-
ing Clin Electrophysiol 1991;14:1905–10.
22. Grimm W, Marchlinski FE. Shock occurrence and survival in 49
patients with idiopathic dilated cardiomyopathy and an implantable
cardioverter-defibrillator. Eur Heart J 1995;16:218–22.
23. Knight B. Outcome of patients with nonischemic cardiology and
unexplained syncope treated with implantable defibrillator. J Am Coll
Cardiol 1999;33:1964–70.
24. Gregoratos G, Cheitlin MS, Conill A, et al. ACC/AHA guidelines
for implantation of cardiac pacemakers and antiarrhythmia devices: a
1972 Josephson JACC Vol. 33, No. 7, 1999
Editorial Comment June 1999:1971–3
report of the ACC/AHA Task Force on Practice Guidelines (Committee
on Pacemaker Implantation). J Am Coll Cardiol 1998;31:1175–206.
25. The Antiarrhythmic versus Implantable Defibrillators (AVID) Inves-
tigators. A comparison of antiarrhythmic-drug therapy with implant-
able defibrillators in patients resuscitated from near-fatal ventricular
arrhythmias. N Engl J Med 1997;337:1576–83.
26. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an
implantable defibrillator in patients with coronary artery disease at high
risk for ventricular arrhythmia. N Engl J Med 1996;335:1933–40.
27. Strickberger SA, Hummel JD, Daoud E, et al. Implantation of 100
consecutive cardioverter defibrillators with nonthoracotomy lead sys-
tems. Circulation 1994;90:868–72.
28. Pacifico A, Wheelan KR, Nasir N, et al. Long-term follow-up of
cardioverter-defibrilator implanted under conscious sedation in
prepectoral subfascial position. Circulation 1997;95:946–50.
29. Kupersmith J, Hogan A, Guerro P, et al. Evaluating and improving
the cost effectiveness of the implantable cardioverter-defibrillator. Am
Heart J 1995;130:507–15.
1973JACC Vol. 33, No. 7, 1999 Josephson
June 1999:1971–3 Editorial Comment
